Daily oral emtricitabine/tenofovir preexposure prophylaxis and herpes simplex virus type 2 among men who have sex with men.

PubWeight™: 1.09‹?› | Rank: Top 10%

🔗 View Article (PMC 3956614)

Published in PLoS One on March 17, 2014

Authors

Julia L Marcus1, David V Glidden2, Vanessa McMahan3, Javier R Lama4, Kenneth H Mayer5, Albert Y Liu6, Orlando Montoya-Herrera7, Martin Casapia8, Brenda Hoagland9, Robert M Grant10

Author Affiliations

1: Gladstone Institute of Virology and Immunology, San Francisco, California, United States or America; University of California, Berkeley, California, United States of America.
2: University of California San Francisco, San Francisco, California, United States of America.
3: Gladstone Institute of Virology and Immunology, San Francisco, California, United States or America.
4: Asociación Civil Impacta Salud y Educación, Lima, Peru.
5: Fenway Institute, Fenway Health, Boston, Massachusetts, United States of America; Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America.
6: Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States of America.
7: Fundación Ecuatoriana Equidad, Guayaquil, Guayas, Ecuador.
8: Asociación Civil Selva Amazónica, Iquitos, Peru.
9: Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil.
10: Gladstone Institute of Virology and Immunology, San Francisco, California, United States or America; University of California San Francisco, San Francisco, California, United States of America.

Associated clinical trials:

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19

Multiple imputation using chained equations: Issues and guidance for practice. Stat Med (2010) 17.36

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med (2010) 12.08

Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS (2006) 10.56

Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet (2008) 9.17

Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79

Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J Infect Dis (2001) 6.35

Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med (2012) 6.29

Genital herpes. Lancet (2007) 3.83

An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ (2008) 3.62

MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS One (2013) 2.39

Seroprevalence of herpes simplex virus type 2 among persons aged 14-49 years--United States, 2005-2008. MMWR Morb Mortal Wkly Rep (2010) 1.91

Herpes simplex virus type 2 (HSV-2) Western blot confirmatory testing among men testing positive for HSV-2 using the focus enzyme-linked immunosorbent assay in a sexually transmitted disease clinic. Sex Transm Dis (2005) 1.91

Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication. Cell Host Microbe (2011) 1.74

Herpes simplex virus type 2: epidemiology and management options in developing countries. Sex Transm Infect (2006) 1.56

Performance of HerpeSelect and Kalon assays in detection of antibodies to herpes simplex virus type 2. J Clin Microbiol (2008) 1.24

No impact of oral tenofovir disoproxil fumarate on herpes simplex virus shedding in HIV-infected adults. AIDS (2011) 1.22

Prevalence and correlates of herpes simplex virus type 2 infection: evaluation of behavioural risk factors. Int J Epidemiol (1998) 1.21

The clinical pharmacology of antiretrovirals for HIV prevention. Curr Opin HIV AIDS (2012) 1.14

Factors associated with herpes simplex virus type 2 incidence in a cohort of human immunodeficiency virus type 1-seronegative Kenyan men and women reporting high-risk sexual behavior. Sex Transm Dis (2011) 1.12

Prevalence and risk factors for herpes simplex infection among patients at high risk for HIV infection in Brazil. Int J Dermatol (2011) 0.83

Articles by these authors

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis (2014) 2.71

No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS One (2013) 2.25

The risk of stable partnerships: associations between partnership characteristics and unprotected anal intercourse among men who have sex with men and transgender women recently diagnosed with HIV and/or STI in Lima, Peru. PLoS One (2014) 0.90

Acceptability and feasibility of HIV self-testing among men who have sex with men in Peru and Brazil. Int J STD AIDS (2015) 0.89

Client and provider perspectives on new HIV prevention tools for MSM in the Americas. PLoS One (2015) 0.84

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. Clin Infect Dis (2016) 0.78

Sexual Orientation, Gender Identity and Perceived Source of Infection Among Men Who Have Sex with Men (MSM) and Transgender Women (TW) Recently Diagnosed with HIV and/or STI in Lima, Peru. AIDS Behav (2016) 0.77

Validation of the 'drinking expectancy questionnaire for men who have sex with men' in Peru. Drug Alcohol Rev (2015) 0.75

Determinants of first trimester attendance at antenatal care clinics in the Amazon region of Peru: A case-control study. PLoS One (2017) 0.75

Partner-Level Factors Associated with Insertive and Receptive Condomless Anal Intercourse Among Transgender Women in Lima, Peru. AIDS Behav (2016) 0.75

Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men. AIDS Behav (2017) 0.75

Brief Participant-Centered Convergence Interviews Integrate Self-Reports, Product Returns, and Pharmacokinetic Results to Improve Adherence Measurement in MTN-017. AIDS Behav (2017) 0.75

Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial? J Am Med Inform Assoc (2017) 0.75

Factors Supporting and Hindering Adherence to Rectal Microbicide Gel Use with Receptive Anal Intercourse in a Phase 2 Trial. AIDS Behav (2017) 0.75